Home » Research Area » » Ion Channels » Ligand-gated Ion Channels » Glutamate (Ionotropic) Receptors » NMDA Receptors » HU 211

HU 211

Cat. No. 2861

Price and Availability

For HU 211 pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: Dexanabinol

Chemical Name: (6aS,10aS)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol

Biological Activity

NMDA antagonist (IC₅₀ = 11 μM for inhibition of [³H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC₅₀ = 3.8 μM) and enhances dopamine D₁ receptor activity. Inhibits NF-κB, reducing TNF-α, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.

Technical Data

M.Wt:

386.57

Formula:

C₂₅H₃₈O₃

Solubility:

Soluble to 100 mM in DMSO and to 100 mM in ethanol

Purity:

>97 %

Storage:

Store at -20°C

CAS No:

112924-45-5

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Eshhar et al (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5 237. PMID: 8298080.

Gallily et al (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J.Pharmacol.Exp.Ther. 283 918. PMID: 9353414.

Striem et al (1997) Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. Eur.J.Pharmacol. 338 205. PMID: 9424014.

Juttler et al (2004) The cannabinoid dexanabinol is an inhibitor of the nuclear factor kappa B (NF-κB). Neuropharmacology 47 580. PMID: 15380375.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Cytokine and NF-κB Signaling Glutamate (Ionotropic) Receptors NF-κB & IκB

NMDA Receptors Transcription Factors

Keywords: HU 211, supplier, NF-κB, NF-kappaB, NF-kB, inhibitors, decreases, TNF-α, TNF-alpha, IL-6, NO, production, NMDA, antagonists, receptors, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, HU211

Quick Order

Find multiple products by catalog number

Pain Research Product Guide

Highlights over 280 products for Pain research. Request copy or view PDF today.

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

Neurobiology of Parkinson's Disease

Written by A. Schapira

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.